Ipilimumab

Generic Name: Ipilimumab

Brand Names: Yervoy

Drug Type: Biotech

Chemical Formula: -

CAS Number: 477202-00-9

Unique Ingredient Identifier: 6T8C155666

Background: Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.

Ipilimumab was granted FDA approval on 25 March 2011.

Indication: Ipilimumab is indicated in the following cancerous conditions:

Melanoma

Renal Cell Carcinoma (RCC)

Colorectal Cancer

Hepatocellular Carcinoma

Non-Small Cell Lung Cancer (NSCLC)

Malignant Pleural Mesothelioma

Esophageal Cancer
...

Associated Conditions: Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)

Associated Therapies: First Line Chemotherapy

Clinical Trials

Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma

Phase 1

Withdrawn

Conditions: Metastatic Melanoma

Interventions: Drug: Anti-OX40
Drug: Ipilimumab

First Posted Date: 2012-09-21

Last Posted Date: 2014-04-01

Lead Sponsor: Ludwig Institute for Cancer Research

Registration Number: NCT01689870

Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer

Phase 1

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Ipilimumab

First Posted Date: 2012-09-20

Last Posted Date: 2024-10-08

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 57

Registration Number: NCT01688492

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Northwestern University, Evanston, Illinois, United States
🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma

Phase 2

Completed

Conditions: Melanoma

Interventions: Drug: Ipilimumab
Drug: Dacarbazine

First Posted Date: 2012-09-07

Last Posted Date: 2015-06-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 21

Registration Number: NCT01681212

Locations: 🇯🇵
Local Institution, Chuo-shi, Yamanashi, Japan

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Phase 2

Completed

Conditions: Melanoma

Interventions: Drug: Ipilimumab
Biological: Vemurafenib

First Posted Date: 2012-08-28

Last Posted Date: 2018-07-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 70

Registration Number: NCT01673854

Locations: 🇺🇸
University Hospitals Of Cleveland, Cleveland, Ohio, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States

and more 11 locations

An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer

Phase 1

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Biological: Nivolumab
Drug: Cabozantinib
Drug: Sorafenib
Drug: Ipilimumab

First Posted Date: 2012-08-07

Last Posted Date: 2024-11-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 659

Registration Number: NCT01658878

Locations: 🇺🇸
Local Institution - 0002, Ann Arbor, Michigan, United States
🇺🇸
Local Institution - 0008, Los Angeles, California, United States
🇺🇸
Local Institution - 0048, Washington, District of Columbia, United States

and more 57 locations

PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma

Phase 1

Completed

Conditions: Advanced Melanoma
Metastatic Melanoma

Interventions: Biological: Nivolumab
Drug: Ipilimumab

First Posted Date: 2012-06-18

Last Posted Date: 2024-04-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 170

Registration Number: NCT01621490

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇳🇱
Local Institution - 0016, Amsterdam, Netherlands
🇺🇸
University Of Chicago, Chicago, Illinois, United States

and more 11 locations